<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01577836</url>
  </required_header>
  <id_info>
    <org_study_id>AOI/2011/SD-03</org_study_id>
    <secondary_id>2011-A01385-36</secondary_id>
    <nct_id>NCT01577836</nct_id>
  </id_info>
  <brief_title>Medico-economic Comparison of Robot-assisted Radical Prostatectomy Versus Radical Prostatectomy Via Laparotomy</brief_title>
  <acronym>RoboProstate</acronym>
  <official_title>Medico-economic Comparison of Robot-assisted Radical Prostatectomy Using the da Vinci System Versus Radical Prostatectomy Via Laparotomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of the study is to estimate and compare the overall cost of care of
      patients over 24 months of follow-up between two groups: (1) patients undergoing
      robot-assisted radical prostatectomy using the Da Vinci system versus (2) patients undergoing
      robot-assisted radical prostatectomy via laparotomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The secondary objectives of this research are to compare the following between the two
      groups:

        -  The actual cost of the surgical prostatectomy.

        -  Erectile function at 0, 1, 6, 12 and 24

        -  Oncological results at 1, 6, 12 and 24 months.

        -  Functional results at 0, 1, 6, 12 and 24 months.

        -  Quality of life at 0, 1, 6, 12 and 24 months.

        -  Complication rates at 1 and 24 months.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall cost (€) of patient care</measure>
    <time_frame>24 months</time_frame>
    <description>Cost of surgical treatment of localized prostate cancer by radical prostatectomy (robot-assisted or conventional retropubic laparotomy) and its follow-up for 2 years. All medical resources consumed will be evaluated during the first 2 years after surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cost (€) of surgery via micro-costing</measure>
    <time_frame>Day 1</time_frame>
    <description>All human and material resources necessary for carrying out a prostatectomy will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in erectile function</measure>
    <time_frame>baseline to 1 month</time_frame>
    <description>the International Index of Erectile Function (IIEF-15) will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in erectile function</measure>
    <time_frame>baseline to 6 months</time_frame>
    <description>the International Index of Erectile Function (IIEF-15) will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in erectile function</measure>
    <time_frame>baseline to 12 months</time_frame>
    <description>the International Index of Erectile Function (IIEF-15) will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in erectile function</measure>
    <time_frame>baseline to 24 months</time_frame>
    <description>the International Index of Erectile Function (IIEF-15) will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the % of positive margins after resection</measure>
    <time_frame>baseline (Day 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence/absence of PSA (Prostate Specific Antigen ) &gt; 0.2 ng/ml (recurrence)</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence/absence of PSA (Prostate Specific Antigen ) &gt; 0.2 ng/ml (recurrence)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence/absence of PSA (Prostate Specific Antigen ) &gt; 0.2 ng/ml (recurrence)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence/absence of PSA (Prostate Specific Antigen ) &gt; 0.2 ng/ml (recurrence)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in function as estimated by the PR25 questionnaire</measure>
    <time_frame>baseline to 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in function as estimated by the PR25 questionnaire</measure>
    <time_frame>baseline to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in function as estimated by the PR25 questionnaire</measure>
    <time_frame>baseline to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in function as estimated by the PR25 questionnaire</measure>
    <time_frame>baseline to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life as estimated by the QLQC-30 questionnaire</measure>
    <time_frame>baseline to 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life as estimated by the QLQC-30 questionnaire</measure>
    <time_frame>baseline to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life as estimated by the QLQC-30 questionnaire</measure>
    <time_frame>baseline to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life as estimated by the QLQC-30 questionnaire</measure>
    <time_frame>baseline to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence/absence of complications (Clavien)</measure>
    <time_frame>1 month</time_frame>
    <description>The Clavien classification will be used (Clavien, P.A., Sanabria J.R., et S.M. Strasberg. 1992. Proposed classification of complications of surgery with examples of utility in cholecystectomy. Suregry 111 (5): 518-526.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence/absence of complications (Clavien)</measure>
    <time_frame>24 months</time_frame>
    <description>The Clavien classification will be used (Clavien, P.A., Sanabria J.R., et S.M. Strasberg. 1992. Proposed classification of complications of surgery with examples of utility in cholecystectomy. Suregry 111 (5): 518-526.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence/absence of complications (Pentafecta)</measure>
    <time_frame>1 month</time_frame>
    <description>The Pentafecta classification will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence/absence of complications (Pentafecta)</measure>
    <time_frame>24 months</time_frame>
    <description>The Pentafecta classification will be used.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">90</enrollment>
  <condition>Prostatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>Robotic assistance, Nîmes</arm_group_label>
    <description>The patients in this group will undergo robot-assisted radial prostatectomy at the University Hospital of Nîmes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Laparotomy, Marseilles</arm_group_label>
    <description>The patients in this group will undergo radical prostatectomy via traditional laparotomy at the University Hospital Marseillles.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Men between the ages of 45 and 75 and who have been diagnosed with localised prostate
        cancer. The treatment option retained is radical prostatectomy.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient must have given his informed and signed consent

          -  The patient must be insured or beneficiary of a health insurance plan

          -  The patient is available for 24 months of follow up

          -  Patient has localised prostate cancer

          -  Patient is eligible for radical prostatectomy

        Exclusion Criteria:

          -  The patient is participating in another study

          -  The patient is in an exclusion period determined by a previous study

          -  The patient is under judicial protection, under tutorship or curatorship

          -  The patient refuses to sign the consent

          -  It is impossible to correctly inform the patient

          -  Patient has a contraindication for a treatment necessary for this study

          -  Patients with psychiatric disorders
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stéphane Droupy, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Nîmes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>APHM - Hôpital de la Conception</name>
      <address>
        <city>Marseille Cedex 5</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Beau Soleil</name>
      <address>
        <city>Montpellier</city>
        <zip>34070</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nîmes - Hôpital Universitaire Carémeau</name>
      <address>
        <city>Nîmes Cedex 09</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2012</study_first_submitted>
  <study_first_submitted_qc>April 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2012</study_first_posted>
  <last_update_submitted>May 19, 2016</last_update_submitted>
  <last_update_submitted_qc>May 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Radical prostatectomie</keyword>
  <keyword>Robotic assistance</keyword>
  <keyword>Laparotomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

